The Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC): (ORR) of 97% from Post-Hoc Analysis of a Phase 2 to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC). (2025). SKIN The Journal of Cutaneous Medicine, 9(2), s565. https://doi.org/10.25251/skin.10.supp.565